The Cambridge, Massachusetts- based Biotechnology company, Moderna, is nearly completing its race in procuring a vaccine against the global pandemic that pestered the whole world's lives, the Novel Coronavirus or COVID-19. Moderna is confident to deliver its promise of 20 million vaccine dosages but is facing a glooming possibility of being shy from November's US National Elections.
The biotech company, Moderna will soon invalidate President Donald J. Trump's optimism and belief that a vaccine would be readily available just-in-time for the November election. The biotech company admits that it will be short by a month or two after the November deadline.
According to Daily Mail, the company confirmed on Friday that the country would receive its massive shares of the 20 million vaccine dosages by the end of 2020. That is the earliest possible timeline that Moderna has set for the vaccine's readiness and supply. The company also aims to produce a whopping 500-million vaccine dosages for the whole world by 2021.
Moderna's vaccine trials have reached its third and final stage, the human trials, which enrolled 25,296 people in its 30,000 participant goal as of last Wednesday, September 16. The trial's sample size would be sufficient to know and determine the data needed by its scientists and researchers for the vaccine's effectivity.
The biotech company's COVID-19 vaccine would be available by October's end. However, that timeline would not be sufficient enough to release the vaccine for mass, public use.
Moderna's COVID-19 Vaccine
The biotech company's efforts in procuring a vaccine are nearing its fruits of labor as it boasts of a promising vaccine that can be made available for 20 million dosages. The coronavirus (COVID-19) has already claimed more than 900,000 lives worldwide and a massive number of people in the country alone.
Moderna's CEO, Stephane Bancel, told CNBC in an interview last Thursday that the infection rates in the US would be a massive factor in the vaccine trials. In case the US infection rate drops, Moderna's vaccine would face hardship in determining and studying its human trials. Moderna's 53 participants are needed to catch and test positive for COVID-19 to determine the vaccine's effectivity.
The company's sample included placebo-vaccinated individuals who will confirm whether those who got the real COVID vaccine are less likely to get sick and be affected by the SARS-CoV2 virus.
Moderna's race to procure a vaccine goes neck and neck with AstraZeneca and Pfizer, completing the trinity of the world's leading vaccine developers. All three companies are in the third and final stage of testing, with Pfizer and Moderna being the forefront in vaccine innovation.
Moderna's Vaccine Supply
The biotech company would be able to produce 20 million of its target 500 million vaccine dosages and made available by 2020, according to Moderna itself. Moderna is known to have a deal with the United States to produce 100 million dosages for the country alone.
The Center for Disease Control and Prevention (CDC) said that as much as 45 million dosages would be ready for approval from the agency, and would receive authorization as it delivers by the end of the year.
This article is owned by Tech Times
Written by Isaiah Alonzo